Sanofi Regeneron:
Dupixent Brochure

I leveraged the branded campaign for a different indication for DUPIXENT, while highlighting the key benefits for this disease, prurigo nodularis. While stock photography was used, the copy reflects real patient quotes. Copy also features the key data important to the HCP audience.

_______

Help Patients Achieve Real Change with DUPIXENT, the first and only biologic approved for the treatment of prurigo nodularis,

Improvement in itch, nodules and QOL 

• Patients achieved significant improvement in itch as early as Week 4 (PRIME)

Unique safety profile

• Consistent with 4 other DUPIXENT indications

• 0% discontinuation due to AEs vs placebo

Start with ease, stay with confidence

• No requirements for initial lab testing or ongoing lab monitoring

• Targeted immunomodulator, avoids broad immunosuppression